Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2-encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2025-10-15
DOI
https://doi.org/10.1158/2159-8290.cd-25-0605
Citations
4
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
6.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Kirstin Petersen, Kristýna Kotýnková, Sven Golfier, Heidi Greulich et al.
4 citations
Cancer Discovery
Lung Cancer Treatments and Mutations
6.07
article

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Kirstin Petersen, Kristýna Kotýnková, Sven Golfier, Heidi Greulich, Markus Berger, Bethany Kaplan, Timothy A. Lewis, Paolo Grassi, Andrew D. Cherniack, Knut Eis, Herbert H. Loong, Kōichi Goto, Dominik Rüttinger, Sawyer Andersen, Jérémie Mortier, R.C. Hillig, Franziska Siegel, Matthew Meyerson, Gizem Karsli Uzunbas, Ulf Boemer, D.R. Denney, Sybil M. Genther Williams, Daniel Korr, Stephan Siegel, Volker Schulze, H Tomono
article en
4 citations

Abstract

Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2-encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.

Cancer DiscoveryVol. 16(1)
Broad Institute (US), eBay (Ireland) (IE), Bayer (United States) (US), Chinese University of Hong Kong (HK), Meyer Children's Hospital (IT), Dana-Farber Cancer Institute (US), Bayer (Italy) (IT), Nuvisan (Germany) (DE), National Cancer Center Hospital East (JP), Bayer (Germany) (DE)
Openalex Percentile: Top 3%
Lung Cancer Treatments and Mutations
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.